Presentation
13 March 2024 Photodynamic priming synergizes with anti-PD1 therapy to improve survival in a preclinical pancreatic tumor model
Author Affiliations +
Proceedings Volume PC12843, Biophotonics and Immune Responses XIX; PC1284307 (2024) https://doi.org/10.1117/12.3003546
Event: SPIE BiOS, 2024, San Francisco, California, United States
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive desmoplasia which is considered to be a primary cause of treatment resistance observed in these tumors. Desmoplasia also plays a major role in mediating an immunosuppressive microenvironment and restricting immune cell infiltration in PDAC. In this study, using a syngeneic orthotopic immunocompetent KPC PDAC model, we demonstrate that PDT using Visudyne® can alter the tumor microenvironment, enhances immune cell infiltration, significantly reducing tumor growth and increasing survival in combination with anti-PD1.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Mohammad A. Saad, Tessa D. van Bergen, Jimena Nicolás Morala, Harrison J. Roberts, Derek Allen, Zhiming Mai, and Tayyaba Hasan "Photodynamic priming synergizes with anti-PD1 therapy to improve survival in a preclinical pancreatic tumor model", Proc. SPIE PC12843, Biophotonics and Immune Responses XIX, PC1284307 (13 March 2024); https://doi.org/10.1117/12.3003546
Advertisement
Advertisement
KEYWORDS
Photodynamic therapy

Tumors

Cancer

Modulation

Molecules

Matrices

Medical statistics

Back to Top